Management of chronic hepatitis B

[Guest guest]

Eur J Gastroenterol Hepatol. 2011 May 19. [Epub ahead of print]

Management of chronic hepatitis B.

Massoumi H, P, Tan HH.

Source

aDivision of Gastroenterology and Hepatology, Albert Einstein College of

Medicine, Bronx, New York b School of Medicine, University of Miami,

Miami, Florida, USA cDepartment of Gastroenterology and Hepatology, Singapore

General Hospital, Singapore.

Abstract

Chronic hepatitis B continues to be a major global health burden. It accounts

for a substantial impact on health care resources and finances in many parts of

the world including Europe. Natural history and disease spectrum are varied,

depending on when and how the infection is acquired. The chronic infective state

increases patients' risk of progression to liver cirrhosis or hepatocellular

carcinoma. Several treatment options are currently available, but their use

depends on the stage of the patient's infection, which is influenced by both

host and viral factors. The ultimate goals in hepatitis B treatment are to

prevent disease progression, hepatic decompensation, hepatocellular carcinoma,

and death. Patients with decompensated liver cirrhosis should be referred to

specialized transplant centers in a timely manner.

PMID: 21602690 [PubMed - as supplied by publisher]

[Guest guest]

Eur J Gastroenterol Hepatol. 2011 May 19. [Epub ahead of print]

Management of chronic hepatitis B.

Massoumi H, P, Tan HH.

Source

aDivision of Gastroenterology and Hepatology, Albert Einstein College of

Medicine, Bronx, New York b School of Medicine, University of Miami,

Miami, Florida, USA cDepartment of Gastroenterology and Hepatology, Singapore

General Hospital, Singapore.

Abstract

Chronic hepatitis B continues to be a major global health burden. It accounts

for a substantial impact on health care resources and finances in many parts of

the world including Europe. Natural history and disease spectrum are varied,

depending on when and how the infection is acquired. The chronic infective state

increases patients' risk of progression to liver cirrhosis or hepatocellular

carcinoma. Several treatment options are currently available, but their use

depends on the stage of the patient's infection, which is influenced by both

host and viral factors. The ultimate goals in hepatitis B treatment are to

prevent disease progression, hepatic decompensation, hepatocellular carcinoma,

and death. Patients with decompensated liver cirrhosis should be referred to

specialized transplant centers in a timely manner.

PMID: 21602690 [PubMed - as supplied by publisher]